Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
3,535 USD | +1,00 % | +4,75 % | +112,65 % |
Kurzporträt
Mitarbeiterzahl: 28
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Joel Lewis
CEO | Chief Executive Officer | 54 | 01.12.17 |
Jack Callicutt
DFI | Director of Finance/CFO | 56 | 01.07.13 |
Ezra R. lowe
CTO | Chief Tech/Sci/R&D Officer | - | - |
Pol Boudes
CTO | Chief Tech/Sci/R&D Officer | 67 | 02.03.20 |
Harold Shlevin
BRD | Director/Board Member | 75 | 01.10.12 |
Susan Thornton
LAW | General Counsel | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Kevin Freeman
BRD | Director/Board Member | 62 | 01.05.11 |
Benjamin Carson
BRD | Director/Board Member | 73 | 07.12. |
Gil Omenn
BRD | Director/Board Member | 83 | 23.09.14 |
Gilbert Amelio
BRD | Director/Board Member | 81 | 12.02.09 |
Harold Shlevin
BRD | Director/Board Member | 75 | 01.10.12 |
Dick Uihlein
CHM | Chairman | 79 | 14.12.17 |
Marc Rubin
BRD | Director/Board Member | 69 | 12.10.11 |
Kary Eldred
BRD | Director/Board Member | 50 | 01.01.18 |
Richard Zordani
BRD | Director/Board Member | 52 | 01.09.20 |
Elissa Schwartz
BRD | Director/Board Member | 54 | 01.09.20 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 0 | 1 235 000 | 0 | 0 | 67,53 % |
Aktie B | 1 | 61 903 672 | 42 636 943 ( 68,88 %) | 0 | |
Aktie C | 0 | 176 | 0 | 0 |
Unternehmenskontakt
Galectin Therapeutics, Inc.
4960 Peachtree Industrial Boulevard Suite 240
30071, Norcross
+678 620 3186
http://www.galectintherapeutics.comSektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+112,65 % | 217 Mio. | |
+2,21 % | 42,59 Mrd. | |
+8,11 % | 40,65 Mrd. | |
+49,22 % | 40,57 Mrd. | |
-12,36 % | 26,77 Mrd. | |
+9,48 % | 24,81 Mrd. | |
-24,48 % | 18,17 Mrd. | |
+28,14 % | 12,05 Mrd. | |
-3,10 % | 11,7 Mrd. | |
+6,86 % | 11,1 Mrd. |
- Börse
- Aktien
- A1JV3R Aktie
- Unternehmen Galectin Therapeutics Inc.